Event in Progress:
Discover the latest content that has just been published on Research Tree
Feature article: 2022 Pharma Statistics - 8.7% growth – but worrying signs An efficient reporting system has seen all the listed multinational pharmaceutical companies announcing results for 2022, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of the global and US rankings of the top 20 drug companies for 2022. 2022 was characterised by 8.7% underlying growth, offset by a large forex impact (-12%), due to USD stren
Companies: PIN HAT ME AVO APAX 4503 BHC 4568 FCSS GLXO HLUNB HIK HZNP IBT JAZZ JAZZ JNJ JNJ 4578 REGN REGN STX 4507 4506 4502 TEVA UTHR UTHR VRTX VRTX VTRS UCB UCB SAN SAN PFE PFE PFIZ NOVOB NOVOB NOT MRNA MRNA MRK
Hardman & Co
While operating in a difficult foreign exchange environment, Pfizer maintained a good operational performance in the second quarter and delivered an all-around beat, exceeding Wall Street expectations on all counts. The management is taking various actions to further strengthen its position as a scientific leader through the continuing introduction of new technologies especially in the anti-viral domain after its success with Covid-19. Fortunately, most of the mutations have resulted in less ser
Companies: Pfizer Inc (PFE:NYSE)Pfizer Inc. (PFE:NYS)
Baptista Research
Pfizer had a phenomenal 2021 given the upside of the Covid-19 vaccine and medication. An estimated 1.4 billion patients have been reached by the company with its vaccines and medicines. Pfizer’s position has been upgraded from fourth to second over big bio-pharmacy companies. In R&D, its investments have been increased, and it has started 13 pivotal clinical studies. The company is increasing its investments in Covid-19 medication, Paxlovid and widening its distribution. The strength of the comp
Companies: Pfizer Inc. (0Q1N:LON)Pfizer Inc. (PFE:NYS)
Pfizer surged past the target price from our last report as the company had strong third quarter, with a 130% increase in operational revenue compared to 2020. Its operational revenue grew by 7% compared to the previous year's quarter even after excluding direct sales and alliance revenues from their Covid-19 vaccine. The company is on track to create 3 billion doses this year, with at least 1 billion going to low-income and middle-income countries. Additionally, their weekly market share of Cov
Pfizer delivered an outstanding second quarter and generated 10% operational revenue growth compared to the same quarter of 2020. The company continued to accelerate the production and delivery of the Pfizer-BioNTech Covid-19 vaccine. It is worth highlighting that the company has already shipped over 1 billion doses since December 2021 and this vaccine alone has contributed $7.8 billion in global revenues during the second quarter. The company is awaiting FDA approval after submitting the late-s
Pfizer is one of the largest pharmaceutical companies in the world by market capitalization and has gained a lot of steam over the past few quarters given its success on the Covid-19 vaccine front. While its revenue growth from the past few years was relatively slow on account of the sale of its consumer healthcare business as well as its generic drugs business, there is a robust upside expected from the success of many of its key drugs such as Ibrance, Vyndaqel, Eliquis, Xeljanz, and Vyndaqel.
The cancer burden is growing globally. Each year >18 million people are diagnosed, nearly 10 million die and the estimated economic cost exceeds $1 trillion. From early diagnosis to late-stage disease, cancer care often involves inappropriate or unnecessary interventions that drive costs but provide limited clinical benefit. Coupled with an increased understanding of cancer biology and rapid technological advances, this has been driving momentum for precision medicine, leading to patient and soc
Companies: IMM IBAB 0O8G BCART 0QLR RHO5 MRCK 0QXH VSC 0QGJ SANO 0OCQ IPH GSK AZN 0Y6X QGEN 0HL9 0GRZ EJXB 0Q15 ABBV 0HAV 0RIH 0R0T BMYS EXK 0J8Z 0R29 0R34 0K3W NSTGQ 0KCC 0Q1N SGEN 0R0H 12V VNRX XE9
goetzpartners securities Limited
Research Tree provides access to ongoing research coverage, media content and regulatory news on Pfizer Inc.. We currently have 0 research reports from 5 professional analysts.
Share: